ETON
NASDAQEton Pharmaceuticals Inc.
Price$23.02+0.25 (+1.12%)
02:00 PM07:45 PM
News · 26 weeks43-37%
2025-10-262026-04-19
Mix1990d
- SEC Filings9(47%)
- Other5(26%)
- Insider2(11%)
- Earnings2(11%)
- Leadership1(5%)
Latest news
25 items- SECSEC Form DEF 14A filed by Eton Pharmaceuticals Inc.DEF 14A - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
- INSIDERSEC Form 4 filed by Riedel Norbert G4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
- SECEton Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
- PREton Pharmaceuticals Announces CFO Succession PlanDEER PARK, Ill., April 16, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the appointment of Judith "Judy" M. Matthews as Executive Vice President, Accounting and Finance. Ms. Matthews will assume the role of Chief Financial Officer effective June 1, 2026. The Company's current Chief Financial Officer, James Gruber, will then step down as part of a planned succession. To ensure a seamless transition, Mr. Gruber will remain in his role through May 31, 2026, and will subsequently enter into a six-month consulting agreement
- SECEton Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Eton Pharmaceuticals Inc.SCHEDULE 13G/A - Eton Pharmaceuticals, Inc. (0001710340) (Subject)
- SECSEC Form 10-K filed by Eton Pharmaceuticals Inc.10-K - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
- SECEton Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
- PREton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial ResultsQ4 2025 product sales of $21.3 million, representing 83% growth over Q4 2024Q4 2025 basic GAAP EPS of $0.06, fully diluted GAAP EPS of $0.05, basic non-GAAP EPS of $0.21, fully diluted non-GAAP EPS of $0.19, and Adjusted EBITDA of $6.2 millionLaunched DESMODA™, the first and only FDA-approved desmopressin oral solutionLicensed U.S. rights to Orphan Drug HEMANGEOL®; expected to be accretive to 2026 earningsCompany expects full year 2026 revenue to exceed $110 million with an Adjusted EBITDA margin of over 30%Management to hold conference call today at 4:30pm ET DEER PARK, Ill., March 19, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (NASDAQ:ETON), an innovati
- SECSEC Form S-8 filed by Eton Pharmaceuticals Inc.S-8 - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
- PREton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026DEER PARK, Ill., March 03, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report fourth quarter and full year 2025 financial results on Thursday, March 19, 2026. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT). Participant Call Link: Click Here Webcast: Click Here In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email
- PREton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral SolutionHEMANGEOL® is the only FDA-approved treatment for infantile hemangiomaHEMANGEOL will be commercialized by Eton beginning May 1stHEMANGEOL will be distributed through the company's Eton Cares™ patient support program, which includes a $0 co-pay initiative, to broaden patient access. DEER PARK, Ill., March 02, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced it has in-licensed U.S. commercialization rights to HEMANGEOL® oral solution from Pierre Fabre Medicament Sas ("Pierre Fabre"). HEMANGEOL is an Orphan Drug indicated for
- SECEton Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits8-K - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
- SECEton Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
- PREton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral SolutionDESMODA is the first and only FDA-approved desmopressin oral solutionCommercial launch expected on March 9thDESMODA eliminates tablet splitting and crushing, enabling precise, individualized dosing for patients of all agesThe product is expected to be a significant long-term growth contributor, with potential peak sales of $30-50 million annually and patent protection extending through 2044 DEER PARK, Ill., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the U.S. Food and Drug Administration (FDA) approval of a Ne
- PREton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11thDEER PARK, Ill., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company's executive leadership team will host one-on-one meetings at the Leerink Partners Global Healthcare Conference on Wednesday, March 11, 2026 in Miami, Florida. To schedule a 1x1 meeting with the Company, please contact your Leerink Partners institutional sales representative. About Eton PharmaceuticalsEton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Co
- INSIDERDirector Riedel Norbert G exercised 30,000 in-the-money shares at a strike of $4.42, increasing direct ownership by 600% to 35,000 units (SEC Form 4)4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
- SECEton Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
- PREton Pharmaceuticals Announces Licensing of Rare Disease Product CandidateProduct is currently under review with the FDAPotential approval and launch mid-2026 DEER PARK, Ill., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the licensing of U.S. marketing rights to an ultra-rare disease product candidate. Once approved, the product is expected to be the first and only generic alternative to a product used to treat an ultra-rare condition that impacts fewer than 100 patients in the United States. "This bolt-on asset aligns well with our existing commercial infrastructure, adding another
- INSIDERSEC Form 4 filed by Director Riedel Norbert G4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
- INSIDERSEC Form 4 filed by Director Adams Jennifer Mckie4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
- INSIDERSEC Form 4 filed by Director Casamento Charles J4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
- INSIDERSEC Form 4 filed by Director Maier Paul V4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
- INSIDERSEC Form 4 filed by Chief Commercial Officer Erdogan-Trinkaus Ipek4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
- INSIDERPresident & CEO Brynjelsen Sean covered exercise/tax liability with 5,015 shares, decreasing direct ownership by 0.17% to 2,889,266 units (SEC Form 4)4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)